RESEARCH AND DEVELOPMENT

Since commencing operations in 2008, viDA has been dedicated to the pursuit of first-in-class therapeutics with the potential to address critical medical problems. Building on our expertise on the serine protease family, Granzymes, viDA is expanding its research and development efforts in the field of Granzyme biology under the guiding principle of addressing therapeutic areas with significant unmet medical need, and a validated development path to approval.

 

GRANZYMES
top ^

A major therapeutic platform at viDA is focused towards inhibiting the activity of Granzyme B (GzmB).  Specifically, viDA is developing inhibitors targeting extracellular GzmB to treat a variety of autoimmune and chronic inflammatory diseases including a number of orphan indications.

 

 

 

 

 

 

 

 

INITIAL DEVELOPMENT PROGRAM
top ^

Dermatology

DISCOVERY PROGRAMS
top ^

Chronic Inflammatory Disease

Fibrotic Disease

Autoimmune Disease

GRANZYME BIOLOGY GRANZYME INHIBITION

viDA is a pioneer in research to understand the biology of granzymes, a granule secreted enzyme that in the extracellular  environment  targets and degrades key proteins that make up the extracellular matrix.  Research implicates Granzymes in multiple pathogenic processes. Read More.

viDA continues to expand our library of proprietary inhibitors (small molecule and biological) targeting extracellular GzmB for different routes of administration to treat a variety of diseases in which GzmB-mediated pathologies play a key role.  Read More.